OCUGEN, INC. (OCGN) Operating Margin
- Operating margin · 12 months: Value -1504.08%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1504.08% | Operating income / revenue. Period ending 2026-06-30. $-68.90M ÷ $4.58M × 100 ≈ -1504.08% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -68.90M USD | Operating Income (Loss) |
| Revenue | 4.58M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 43.76M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-68.90M | $4.58M | (m) | $43.76M | (m) | -1504.08% |
| 2026-03-31 | $-66.25M | $4.46M | (m) | $41.48M | (m) | -1483.85% |
| 2025-12-31 | $-62.92M | $4.41M | (m) | $39.75M | (m) | -1425.70% |
| 2025-09-30 | $-59.76M | $5.37M | (m) | $37.37M | (m) | -1112.87% |
| 2025-06-30 | $-55.39M | $4.75M | (m) | $34.33M | (m) | -1165.08% |
| 2025-03-31 | $-57.04M | $4.52M | (m) | $34.83M | (m) | -1261.43% |
| 2024-12-31 | $-54.76M | $4.05M | (m) | $32.13M | (m) | -1350.36% |
| 2024-09-30 | $-52.44M | $4.70M | (m) | (m) | (m) | -1115.79% |
| 2024-06-30 | $-51.62M | $7.26M | (m) | (m) | (m) | -710.74% |
| 2024-03-31 | $-59.71M | $6.61M | (m) | (m) | (m) | -903.77% |
| 2023-12-31 | $-65.53M | $6.04M | (m) | (m) | (m) | -1085.67% |
| 2023-09-30 | $-81.06M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-88.75M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-84.58M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-84.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-75.29M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-62.96M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-69.00M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-58.03M | $0.00 | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-47.26M | $-380.00 | (m) | (m) | (m) | 12437820.26% |
| 2021-06-30 | $-46.66M | $-380.00 | (m) | (m) | (m) | 12278083.42% |
| 2021-03-31 | $-24.41M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-21.28M | $42.62K | (m) | (m) | (m) | -49940.68% |
| 2020-09-30 | $-21.76M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $-14.29M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $-13.25M | (m) | (m) | $5.94M | (m) | (m) |
| 2019-12-31 | $-14.16M | (m) | (m) | $8.09M | (m) | (m) |
| 2019-09-30 | $-29.54M | (m) | (m) | $14.57M | (m) | (m) |
| 2019-06-30 | $-27.84M | (m) | (m) | $9.92M | (m) | (m) |
| 2019-03-31 | $-32.07M | $0.00 | (m) | $13.93M | (m) | (m) |
| 2018-12-31 | $-30.11M | $0.00 | (m) | $15.63M | (m) | (m) |
| 2018-09-30 | $-26.40M | $0.00 | (m) | $15.67M | (m) | (m) |
| 2018-06-30 | $-25.12M | $0.00 | (m) | $14.60M | (m) | (m) |
| 2018-03-31 | $-24.21M | $0.00 | (m) | $14.35M | (m) | (m) |
| 2017-12-31 | $-24.95M | $0.00 | (m) | $15.57M | (m) | (m) |
| 2017-09-30 | $-26.82M | $0.00 | (m) | $17.52M | (m) | (m) |
| 2017-06-30 | $-27.76M | $0.00 | (m) | $18.91M | (m) | (m) |
| 2017-03-31 | $-29.34M | $0.00 | (m) | $20.50M | (m) | (m) |
| 2016-12-31 | $-30.31M | $0.00 | (m) | $21.58M | (m) | (m) |
| 2016-09-30 | $-30.71M | $0.00 | (m) | $22.03M | (m) | (m) |
| 2016-06-30 | $-32.11M | $0.00 | (m) | $23.00M | (m) | (m) |
| 2016-03-31 | $-31.74M | $0.00 | (m) | $23.07M | (m) | (m) |
| 2015-12-31 | $-31.82M | $0.00 | (m) | $23.24M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-32.66M | $0.00 | (m) | $26.04M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |